OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

On the trading front as buyers were paying as much as 9.75p earlier on
the trend has been up on the chart also as share price is holding well abovee 50 days MA,
with all I can see it is still all looking good

Since the beginning of 2018 sp has been in the 12p region..... partly due to their deal in US which is possibly worth "££ots if the Bio gets Regulatory Approval after further dev. That's the way healthcare goes.... Yet it's interesting that a US-Bio is willing to do a deal with what must be OXB's tech... so, it must have fundamental value, IMHO.
If the product is sold in America ( and in Europe, presumably ), the value to OXB will be transforming, as I read it.... Yet the Market has moved only v.slightly -and on the day of the Ann. I recall it went down a few %. Such is Investor demand for "instant Riches" - Ah well . . . . maybe 15p, then 20p . . . who knows?
I'm hoping their Manufacturing position means there won't be any Cash-Calls . . . as this Co. has a reputation for doing precisely that, within weeks of an AGM.
EDIT (14March2018):-sp~12p.... what a difference a week makes! - As soon as my Msg. was posted, we read there is a £20m/11p begging-bowl going the rounds.
Pah! . . . . Didn't they receive the Up-Front money from USA?
The only "bonus" is the March begging-bowl hasn't yet dropped the sp....but I wonder what is supporting it? Usually the sp falls to the Offer-price, (or below!)...but here, the sp rose early 2018....as if the Institutions wanted to spend money. Very Odd... +DYOR.
EDIT(27Apr2018)- Well, almost 12p - hopefully no BB during 2018 after AGM in May .....
EDIT(6May2018)- Oh dear CONsolidation.... 50:1 -DYOR- will this really change anything? shares instantly nearly £7, - which seems silly . . . . OXB isn't in the same league as the Big Boys with Real Turnover, are they? -OR- is this to distance themselves from the 2-pence days? It won't IMHO. It's a CON - since paperwork only adds COST - everything else is the same.... OXB Execs: -Get Selling and the sp will rise without intervention.
EDIT (22May2018)- sp is 15p for no obvious reason . . . Thoughts anyone?
EDIT (24May2018)...sp up 0.5% with trades 9.4m =Buy and 1.4m=Sell, so the Market appears to be Buying.... Could this be the recent deal in US, said to be worth $100m in Royalties.... yet not yet within grasp . . . =OR= does someone know better? . . . . .
EDIT (30May2018)...sp 720p after 50:1 CONsolidation. ....by 14:30 sp drops to 685p...Ooops! - Yet by 31May it's 723p.... was that earlier "drop" a falsie?
EDIT-30th- by end of Trading it's 661p ( Shown as 5% down ).
EDIT (2 June2018)- yet Friday-closing is 694 . . . is this MM's "Shaking the tree"
EDIT (7June2018)-sp 882 after Parkinson Ann, mentioned by cynic and queen2 . . . also the Trades are +ve. Maybe...just maybe this is showing New-OXB is getting there . . . and with these income-anticipations, the sp can only rise - I hope.
EDIT (15June2018)- Well my Theory that CONsolidation NEVER benefits LT-investeors appears to be failing...sp a few pence off £10. that's abt. 50% rise after the 50:1 notional = 720p. I guess Posters here are right - that "potential" is what punters are buying-into. +I just Hope OXB can deliver, with R4 News of Gene-Therapy advances at Kings Col Lon. which never mentioned OXB.
Ho-Ho and my Broker suggested "top-slicing" at 12p ( that's just £6, so I'd have missed the recent +£4 uplift...).
EDIT (21June2018)- up again, now 1050 - doesn't look like jitters are showing...
EDIT (2July2018)- off the high now; despite late June Euro-approval (w. Novatis partner)...There's 3-yr total potential =£100m - Someone's not reacting right?
EDIT (13July2018)-sp 880...so it looks like the sunny days may be over for now. I'll not sell now, although maybe I should have taken the investment out at the £10+ level.... Let's just hope that drug-deal is a good'un...
EDIT (4Jan2019)- 660p doesn't look too good, but no-news does that to a share.
EDIT(25Jan2019)-I read there are more Execs buying (~£25k-worth), Not massive, but helping...
EDIT (18Feb2019)-Oxf Eye Hosp "Gene Th" on TV News, but nothing about their source or any OXB involvement - OXB was active in Macular; but not sure, in 2019....Anyone?

a tasty rns out this morning ......

Oxford BioMedica said it had entered into an exclusive worldwide licensing agreement with Axovant Sciences to develop and commercialisea a gene therapy developed by the company for Parkinson's disease.

The agreement would see Axovant utilise Oxford BioMedica's LentiVector platform.

Under the terms of the agreement, Oxford BioMedica would receive a $30m upfront payment (£22m) including $5m as pre-payment for manufacturing activities related to OXB-102, now renamed, AXO-Lenti-PD.

Oxford BioMedica was also eligible to receive $55m on achievement of development milestones and $757.5m on achievement of regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD.

Game changer. Obviously no guarantees but $757m is potentially stratospheric....